Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 114

Sort by

Sort Order Select

Journal Articles

ACUTE GRAFT Versus Host Disease 1990-2017: Reduced Incidence and Predictive Factors

Alessandra Di Francesco, MD, Andrea Bacigalupo, MD

Blood (2019) 134 (Supplement_1): 4526.

https://doi.org/10.1182/blood-2019-124843

Published: 2019

Journal Articles

Outcome of 673 Patients with Hematologic Malignancies Surviving at Least 8 YEARS Post- Allogeneic Transplants: Risk Factors and Quality of Life

Giuseppe Sapienza, MD, Teresa Lamparelli, Alida Dominietto, MD, Anna Maria Raiola, MD, Carmen Di Grazia, MD, Francesca Gualandi, Simona Sica, MD, Elisabetta Metafuni, Emanuele Angelucci, MD, Andrea Bacigalupo, MD

Blood (2019) 134 (Supplement_1): 4601.

https://doi.org/10.1182/blood-2019-131959

Published: 2019

Journal Articles

Unrelated Cord Blood Transplantation and Post-Transplant Cyclophosphamide (PT-CY)

Patrizia Chiusolo, Andrea Bacigalupo, MD, Simona Sica, MD, Sabrina Giammarco, MD PhD, Elisabetta Metafuni, Federica Sora, MD, Luca Laurenti, MD, Francesco Autore, MD, Idanna Innocenti, MD PhD, Silvia Bellesi, Gina Zini, MD PhD, Maria Bianchi, Caterina Giovanna Valentini, Luciana Teofili, MD

Blood (2019) 134 (Supplement_1): 3332.

https://doi.org/10.1182/blood-2019-130849

Published: 2019

Journal Articles

Full Donor Chimerism after Allografts for Myelofibrosis: The Role of Conditioning Regimen

Patrizia Chiusolo, Sabrina Giammarco, MD PhD, Teresa Lamparelli, Lucia Casarino, Monica Rossi, Alida Dominietto, MD, Anna Maria Raiola, MD, Francesca Gualandi, Carmen Di Grazia, MD, Silvia Betti, MD PhD, Federica Sorà, MD, Elena Rossi, MD PhD, Luciana Teofili, MD, Simona Sica, MD, Andrea Bacigalupo, MD, Emanuele Angelucci, MD

Blood (2019) 134 (Supplement_1): 4490.

https://doi.org/10.1182/blood-2019-126711

Published: 2019

Journal Articles

The Impact of Aminoacid Substitution at Position 116 Class I HLA, in Unrelated Donor Transplants

Patrizia Chiusolo, Teresa Lamparelli, Giuseppe Sapienza, MD, Alida Dominietto, MD, Anna Maria Raiola, MD, Carmen Di Grazia, MD, Sabrina Giammarco, MD PhD, Francesca Gualandi, Elisabetta Metafuni, Monica Rossi, Gessica Minnella, Simona Sica, MD, Andrea Bacigalupo, MD, Emanuele Angelucci, MD

Blood (2019) 134 (Supplement_1): 4620.

https://doi.org/10.1182/blood-2019-130614

Published: 2019

Journal Articles

Unmanipulated Haploidentical Marrow Transplantation with a Modified Post-Transplant Cyclophosphamide (PT-CY) Regimen: An Update on 444 Patients

Andrea Bacigalupo, MD, Anna Maria Raiola, MD, Alida Dominietto, MD, Carmen Di Grazia, MD, Stefania Bregante, Francesca Gualandi, Maria Teresa Van Lint, MD, Patrizia Chiusolo, MD, Luca Laurenti, MD, Federica Sora, Sabrina Giammarco, MD PhD, Simona Sica, MD, Emanuele Angelucci, MD

Blood (2018) 132 (Supplement 1): 3351.

https://doi.org/10.1182/blood-2018-99-118850

Published: 2018

Journal Articles

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Blood (2018) 132 (Supplement 1): 577.

https://doi.org/10.1182/blood-2018-99-111946

Published: 2018

Journal Articles

Risk of Infectious Complications in Patients with Chronic Lymphocytic Leukemia in the Era of BCR Inhibitors: A Retrospective Single Institution Experience

Francesco Autore, MD, Idanna Innocenti, MD PhD, Francesca Morelli, Federica Sora, Andrea Corbingi, MD, Denise Soldati, Luana Fianchi, MD, Marianna Criscuolo, Livio Pagano, Andrea Bacigalupo, MD, Simona Sica, MD, Luca Laurenti, MD

Blood (2018) 132 (Supplement 1): 5552.

https://doi.org/10.1182/blood-2018-99-119654

Published: 2018

Journal Articles

Which Is the Best Mobilizing Regimen in POEMS Syndrome? a Retrospective Italian Study of Two Haematological Centres

Francesco Autore, MD, Nicola Piccirillo, MD, Andrea Nozza, MD, Idanna Innocenti, MD PhD, Rossana Putzulu, MD, Patrizia Chiusolo, MD, Federica Sora, MD, Gina Zini, MD PhD, Andrea Bacigalupo, MD, Luca Castagna, MD, Simona Sica, MD, Stefania Bramanti, MD, Luca Laurenti, MD

Blood (2018) 132 (Supplement 1): 5692.

https://doi.org/10.1182/blood-2018-99-118554

Published: 2018

Journal Articles

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Blood (2018) 132 (Supplement 1): 3032.

https://doi.org/10.1182/blood-2018-99-111929

Published: 2018

Journal Articles

EARLY Post-Transplant Events , Cost of Admission and Mortality, in Patients Undergoing Allogeneic Transplants from Identical Siblings, Unrelated Donors or Haploidentical Donors

Federica SORA, MD, Patrizia Chiusolo, MD, Luca Laurenti, MD, Sabrina Giammarco, MD PhD, Francesco Autore, MD, Idanna Innocenti, MD PhD, Simona Sica, MD, Metafuni Elisabetta, Andrea Bacigalupo, MD

Blood (2018) 132 (Supplement 1): 4648.

https://doi.org/10.1182/blood-2018-99-116506

Published: 2018

Journal Articles

Long-Term Follow-up of the Randomized Controlled Study in Patients with Newly Diagnosed Severe Aplastic Anemia Treated with ATG, Cyclosporine, with or without G-CSF: On Behalf of the SAA Working Party of the EBMT

André Tichelli, MD, Regis Peffault De Latour, Jakob R. Passweg, MD PhD, Cora Knol, Gérard Socié, MDPhD, Judith Marsh, Britta Hoechsmann, MD, Hubert Schrezenmeier, MD, Andrea Bacigalupo, MD, Sujith Samarasinghe, Alicia Rovo, MD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Dirk-Jan Eikema, Paul Bosman, Peter Bader, MD PhD, Antonio M. Risitano, MD PhD, Carlo Dufour, MD

Blood (2018) 132 (Supplement 1): 1307.

https://doi.org/10.1182/blood-2018-99-111811

Published: 2018

Journal Articles

Transplant Outcome for Patients with Acquired Aplastic Anemia over the Age of 40: Mortality HAS NOT Been Reduced in 2015

Sabrina Giammarco, MD PhD, Simona Sica, MD, Carlo Dufour, MD, Regis Peffault De Latour, MD PhD, Gerard Socie, MD PhD, Jakob R. Passweg, MDMS, Andrea Bacigalupo, MD

Blood (2017) 130 (Supplement 1): 3326.

https://doi.org/10.1182/blood.V130.Suppl_1.3326.3326

Published: 2017

Journal Articles

UGT1A1 Polymorphism and Mortality Outcome after Allogeneic Stem Cell Transplantation with Busulfan Based Regimen

Patrizia Chiusolo, Angelo Minucci, Metafuni Elisabetta, Sabrina Giammarco, MD PhD, Monica Rossi, Gessica Minnella, Cecilia Zuppi, Andrea Urbani, Andrea Bacigalupo, MD, Ettore Capoluongo, Simona Sica, MD

Blood (2017) 130 (Supplement 1): 3218.

https://doi.org/10.1182/blood.V130.Suppl_1.3218.3218

Published: 2017

Journal Articles

Reduced Relapse and Improved Survival in Chemosensitive Hodgkin Lymphoma Patients Undergoing Haploidentical Related Donor Compared to HLA-Identical Donor Transplantation

Blood (2017) 130 (Supplement 1): 3309.

https://doi.org/10.1182/blood.V130.Suppl_1.3309.3309

Published: 2017

Journal Articles

Post-Transplant Cyclophosphamide (PT-Cy) for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Transplantation from HLA Identical Sibling and Matched Unrelated Donor for Patients with Acute Leukemia, on Behalf of ALWP-EBMT

Annalisa Ruggeri, MD, Myriam Labopin, MD, Boris V Afanasyev, MD PhD Professor, Jan J Cornelissen, Ahmet Elmaagacli, MD, Maija Itälä-Remes, MD PhD, Didier Blaise, Ellen Meijer, Koc Yener, Noel Milpied, Harry C. Schouten, MD, Nicolaus Kröger, Mohamad Mohty, MD PhD, Andrea Bacigalupo, MD, Arnon Nagler, MD

Blood (2017) 130 (Supplement 1): 215.

https://doi.org/10.1182/blood.V130.Suppl_1.215.215

Published: 2017

Journal Articles

Busulfan Fludarabine (BU-FLU) Compared to Thiotepa Busulfan Fludarabine (TBF) for Allogeneic Transplants in Acute Myeloid Leukemia (AML) or Refractory Anemia with Excess Blasts (RAEB) in Remission

Federica Sora, MD, Simona Sica, MD, Carmen Di Grazia, MD, Patrizia Chiusolo, Luca Laurenti, Nicola Mordini, Attilio Olivieri, Anna Paola Iori, Emanuele Angelucci, Andrea Bacigalupo, MD

Blood (2017) 130 (Supplement 1): 909.

https://doi.org/10.1182/blood.V130.Suppl_1.909.909

Published: 2017

Journal Articles

Association between 9p21 Chromosome Polymorphisms rs1333040 and rs7865618 and Chronic Myeloid Leukemia

Federica SORA, MD, Patrizia Chiusolo, Igor Giarretta, Elisabetta Abruzzese, MD PhD, Sara Marietti, Francesco Autore, Ilaria Gatto, Andrea Bacigalupo, MD, Roberto Pola, Simona Sica, MD

Blood (2017) 130 (Supplement 1): 2866.

https://doi.org/10.1182/blood.V130.Suppl_1.2866.2866

Published: 2017

Journal Articles

Clinical Implications of TP53 Mutations and p53 Dysfunction in Patients with Myelodysplastic Syndrome (MDS). a Study from the Italian MDS Clinical Network

Blood (2017) 130 (Supplement 1): 2959.

https://doi.org/10.1182/blood.V130.Suppl_1.2959.2959

Published: 2017

Journal Articles

Minimal Residual Disease Assessment May Drive Post Remission Therapy in Acute Myeloid Leukemia. It's Time for MRD-Driven Therapy

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Annalisa Kunkl, MD, Filippo Ballerini, MD, Nicoletta Colombo, PhD, Enrico Carminati, Giuseppina Fugazza, Giordana Pastori, MD, Simona Matarrese, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Andrea Bacigalupo, MD, Roberto Massimo Lemoli, MD, Maurizio Miglino, PhD, Marco Gobbi, MD

Blood (2016) 128 (22): 2895.

https://doi.org/10.1182/blood.V128.22.2895.2895

Published: 2016

NARROW

ACUTE GRAFT Versus Host Disease 1990-2017: Reduced Incidence and Predictive Factors

Outcome of 673 Patients with Hematologic Malignancies Surviving at Least 8 YEARS Post- Allogeneic Transplants: Risk Factors and Quality of Life

Unrelated Cord Blood Transplantation and Post-Transplant Cyclophosphamide (PT-CY)

Full Donor Chimerism after Allografts for Myelofibrosis: The Role of Conditioning Regimen

The Impact of Aminoacid Substitution at Position 116 Class I HLA, in Unrelated Donor Transplants

Unmanipulated Haploidentical Marrow Transplantation with a Modified Post-Transplant Cyclophosphamide (PT-CY) Regimen: An Update on 444 Patients

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Risk of Infectious Complications in Patients with Chronic Lymphocytic Leukemia in the Era of BCR Inhibitors: A Retrospective Single Institution Experience

Which Is the Best Mobilizing Regimen in POEMS Syndrome? a Retrospective Italian Study of Two Haematological Centres

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

EARLY Post-Transplant Events , Cost of Admission and Mortality, in Patients Undergoing Allogeneic Transplants from Identical Siblings, Unrelated Donors or Haploidentical Donors

Long-Term Follow-up of the Randomized Controlled Study in Patients with Newly Diagnosed Severe Aplastic Anemia Treated with ATG, Cyclosporine, with or without G-CSF: On Behalf of the SAA Working Party of the EBMT

Transplant Outcome for Patients with Acquired Aplastic Anemia over the Age of 40: Mortality HAS NOT Been Reduced in 2015

UGT1A1 Polymorphism and Mortality Outcome after Allogeneic Stem Cell Transplantation with Busulfan Based Regimen

Reduced Relapse and Improved Survival in Chemosensitive Hodgkin Lymphoma Patients Undergoing Haploidentical Related Donor Compared to HLA-Identical Donor Transplantation

Post-Transplant Cyclophosphamide (PT-Cy) for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Transplantation from HLA Identical Sibling and Matched Unrelated Donor for Patients with Acute Leukemia, on Behalf of ALWP-EBMT

Busulfan Fludarabine (BU-FLU) Compared to Thiotepa Busulfan Fludarabine (TBF) for Allogeneic Transplants in Acute Myeloid Leukemia (AML) or Refractory Anemia with Excess Blasts (RAEB) in Remission

Association between 9p21 Chromosome Polymorphisms rs1333040 and rs7865618 and Chronic Myeloid Leukemia

Clinical Implications of TP53 Mutations and p53 Dysfunction in Patients with Myelodysplastic Syndrome (MDS). a Study from the Italian MDS Clinical Network

Minimal Residual Disease Assessment May Drive Post Remission Therapy in Acute Myeloid Leukemia. It's Time for MRD-Driven Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only